Ikano Therapeutics

Ikano Therapeutics was a specialty pharmaceutical company focused on developing innovative drug delivery systems for established molecules, primarily targeting the central nervous system and pain management. The company's lead product candidate, ITI-111, was an intranasal formulation of midazolam designed for the treatment of acute repetitive seizures, also known as seizure clusters. Ikano's strategy involved utilizing 505(b)(2) regulatory pathways to improve the delivery, safety, and efficacy of known therapeutics. In 2010, the company was acquired by Upsher-Smith Laboratories, which sought to expand its neurology portfolio. The lead asset eventually contributed to the development of the FDA-approved nasal spray Nayzilam.